Compare WYETH LTD with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs CIPLA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD CIPLA WYETH LTD/
CIPLA
 
P/E (TTM) x 27.7 24.3 114.1% View Chart
P/BV x 5.3 2.5 215.5% View Chart
Dividend Yield % 1.3 0.6 196.8%  

Financials

 WYETH LTD   CIPLA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
CIPLA
Mar-19
WYETH LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,044678 154.0%   
Low Rs818484 169.1%   
Sales per share (Unadj.) Rs298.6198.2 150.6%  
Earnings per share (Unadj.) Rs57.218.5 309.0%  
Cash flow per share (Unadj.) Rs58.435.0 167.0%  
Dividends per share (Unadj.) Rs17.003.00 566.7%  
Dividend yield (eoy) %1.80.5 353.5%  
Book value per share (Unadj.) Rs249.5186.3 133.9%  
Shares outstanding (eoy) m22.72805.70 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.9 106.4%   
Avg P/E ratio x16.331.4 51.9%  
P/CF ratio (eoy) x15.916.6 96.0%  
Price / Book Value ratio x3.73.1 119.7%  
Dividend payout %29.716.2 183.4%   
Avg Mkt Cap Rs m21,157468,031 4.5%   
No. of employees `0000.522.6 2.2%   
Total wages/salary Rs m40028,565 1.4%   
Avg. sales/employee Rs Th13,787.47,053.1 195.5%   
Avg. wages/employee Rs Th813.01,261.5 64.4%   
Avg. net profit/employee Rs Th2,643.3659.1 401.1%   
INCOME DATA
Net Sales Rs m6,783159,710 4.2%  
Other income Rs m3534,766 7.4%   
Total revenues Rs m7,136164,475 4.3%   
Gross profit Rs m1,61730,973 5.2%  
Depreciation Rs m2713,263 0.2%   
Interest Rs m61,684 0.3%   
Profit before tax Rs m1,93820,791 9.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6325,695 11.1%   
Profit after tax Rs m1,30114,924 8.7%  
Gross profit margin %23.819.4 122.9%  
Effective tax rate %32.627.4 119.1%   
Net profit margin %19.29.3 205.2%  
BALANCE SHEET DATA
Current assets Rs m6,984124,266 5.6%   
Current liabilities Rs m2,05637,715 5.5%   
Net working cap to sales %72.654.2 134.1%  
Current ratio x3.43.3 103.1%  
Inventory Days Days9991 109.5%  
Debtors Days Days2495 25.2%  
Net fixed assets Rs m244105,190 0.2%   
Share capital Rs m2271,611 14.1%   
"Free" reserves Rs m5,441148,511 3.7%   
Net worth Rs m5,668150,123 3.8%   
Long term debt Rs m2538,301 0.1%   
Total assets Rs m7,901239,633 3.3%  
Interest coverage x353.313.3 2,647.8%   
Debt to equity ratio x00.3 1.7%  
Sales to assets ratio x0.90.7 128.8%   
Return on assets %16.56.9 238.5%  
Return on equity %22.99.9 230.8%  
Return on capital %34.011.8 287.6%  
Exports to sales %0.234.7 0.6%   
Imports to sales %36.30-   
Exports (fob) Rs m1555,419 0.0%   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1557,410 0.0%   
Fx outflow Rs m2,67719,041 14.1%   
Net fx Rs m-2,66238,368 -6.9%   
CASH FLOW
From Operations Rs m92316,911 5.5%  
From Investments Rs m317-16,687 -1.9%  
From Financial Activity Rs m-481-3,487 13.8%  
Net Cashflow Rs m759-3,451 -22.0%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.1 20.8 245.7%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 7.2 23.7 30.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 30.4 26.2 116.0%  
Shareholders   21,978 161,166 13.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   SHASUN PHARMA  STERLING BIOTECH  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  IPCA LABS  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - AUROBINDO PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS